NeurogesX Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 35

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $12.5M

NeurogesX General Information

Description

Developer of novel pain management therapies. The company's lead product includes Qutenza (capsaicin) 8% patch, a non-narcotic analgesic formulated dermal delivery system containing an 8% concentration of synthetic capsaicin.

Contact Information

Formerly Known As
Advanced Analgesics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 2215 Bridgepointe Parkway
  • Suite 200
  • Foster City, CA 94404
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeurogesX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Merger/Acquisition 10-Jul-2013 $12.5M 00000 000.00 Completed Clinical Trials - Phase 3
11. PIPE 08-Feb-2012 000 00000 Completed Clinical Trials - Phase 3
10. PIPE 31-Dec-2011 00000 00000 Completed Profitable
9. Debt - General 09-Aug-2011 0000 00000 Completed Clinical Trials - Phase 3
8. PIPE 30-Apr-2010 0000 00000 Completed Clinical Trials - Phase 3
7. 2PO 13-May-2008 00000 Completed Clinical Trials - Phase 3
6. PIPE 09-Jan-2008 000.00 00000 Completed Clinical Trials - Phase 3
5. IPO 02-May-2007 0000 00000 00000 Completed Clinical Trials - Phase 3
4. Later Stage VC (Series C2) 01-Dec-2005 $20.2M $86.5M 000.00 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series C) 24-Feb-2004 $36M $66.4M 000.00 Completed Clinical Trials - Phase 3
To view NeurogesX’s complete valuation and funding history, request access »

NeurogesX Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C2 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 31,200,000 $0.001000 $0.75 $0.75 1x $0.75 24.74%
Series A 13,946,000 $0.001000 $0.62 $0.62 1x $0.62 9.74%
To view NeurogesX’s complete cap table history, request access »

NeurogesX Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel pain management therapies. The company's lead product includes Qutenza (capsaicin) 8% patch, a non-na
Pharmaceuticals
Foster City, CA
35 As of 2011
00000
000.00 0000-00-00
000000&0 00000

000000

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000 000000000
Cambridge, MA
0 As of 0000
00000
00000000 00000

000000

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
000000000000000
San Mateo, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeurogesX Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Synlogic Formerly VC-backed Cambridge, MA 0 00000 00000000 00000
Talphera Formerly VC-backed San Mateo, CA 00 00000 000000000 00000
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA 000 00000 000000&0 00000
Novo Nordisk Corporation Bagsvaerd, Denmark 00000 000000000
ViaCyte Formerly VC-backed San Diego, CA 000 00000 000000&0 00000
You’re viewing 5 of 5 competitors. Get the full list »

NeurogesX Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeurogesX Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Alta Partners Venture Capital Minority 000 0000 000000 0
California Public Employees' Retirement System Government Minority 000 0000 000000 0
Cross Creek Advisors Venture Capital Minority 000 0000 000000 0
Diamond Capital Management Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

NeurogesX FAQs

  • When was NeurogesX founded?

    NeurogesX was founded in 1998.

  • Where is NeurogesX headquartered?

    NeurogesX is headquartered in Foster City, CA.

  • What is the size of NeurogesX?

    NeurogesX has 35 total employees.

  • What industry is NeurogesX in?

    NeurogesX’s primary industry is Pharmaceuticals.

  • Is NeurogesX a private or public company?

    NeurogesX is a Private company.

  • What is the current valuation of NeurogesX?

    The current valuation of NeurogesX is 000.00.

  • What is NeurogesX’s current revenue?

    The current revenue for NeurogesX is 00000.

  • How much funding has NeurogesX raised over time?

    NeurogesX has raised $219M.

  • Who are NeurogesX’s investors?

    ARCH Venture Partners, Alta Partners, California Public Employees' Retirement System, Cross Creek Advisors, and Diamond Capital Management are 5 of 16 investors who have invested in NeurogesX.

  • Who are NeurogesX’s competitors?

    Synlogic, Talphera, Dicerna Pharmaceuticals, Novo Nordisk, and ViaCyte are competitors of NeurogesX.

  • When was NeurogesX acquired?

    NeurogesX was acquired on 10-Jul-2013.

  • Who acquired NeurogesX?

    NeurogesX was acquired by Acorda Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »